Clinical trial with traditional Chinese medicine intervention ''tonifying the kidney to promote liver regeneration and repair by affecting stem cells and their microenvironment'' for chronic hepatitis B-associated liver failure

Table 6 Biochemical indicators after 8-wk treatment (mean ± SD)

Group	Time	n	PTA (%)	n	TBIL (µmol/L)	n	ALB (g/L)	n	ALT (IU/L)
MMC	Before treatment	28	26.80 ± 10.91	30	326.29 ± 210.47	28	28.07 ± 4.56	30	202.00 ± 249.20
	After treatment	18	43.14 ± 18.60	21	176.13 ± 185.70	21	28.57 ± 4.56	21	39.90 ± 30.19
“TQD”	Before treatment	61	32.50 ± 12.15	65	314.04 ± 160.20	65	29.54 ± 4.75	65	254.80 ± 424.32
	After treatment	55	43.59 ± 22.08	63	242.54 ± 229.05	63	31.30 ± 4.77c	63	78.70 ± 161.80
“TTK”	Before treatment	36	28.63 ± 11.28	36	369.13 ± 198.06	36	27.82 ± 4.52	36	189.52 ± 241.97
	After treatment	30	32.55 ± 15.58	33	339.40 ± 270.09a	33	30.72 ± 2.89e	33	70.12 ± 82.23

Normal range: PTA: 80%-120%; TBIL: 3.4-20.5 μmol/L; ALB: 35-55 g/L; ALT: 0-46 IU/L.

^aP < 0.05 vs MMC group;

^cP < 0.05 vs MMC group,

^eP < 0.05 vs MMC group.